190 related articles for article (PubMed ID: 24291998)
1. [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].
Doi H; Sakakibara R; Kishi M; Tsuyuzaki Y; Tateno F; Hirai S
Rinsho Shinkeigaku; 2013; 53(11):1382-5. PubMed ID: 24291998
[TBL] [Abstract][Full Text] [Related]
2. Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.
Tanaka Y; Kato T; Nishida H; Araki H; Murase M; Nagaki M; Moriwaki H; Inuzuka T
J Neurol; 2009 Dec; 256(12):1972-6. PubMed ID: 19575260
[TBL] [Abstract][Full Text] [Related]
3. Gastric emptying time and gastric motility in patients with Parkinson's disease.
Hardoff R; Sula M; Tamir A; Soil A; Front A; Badarna S; Honigman S; Giladi N
Mov Disord; 2001 Nov; 16(6):1041-7. PubMed ID: 11748735
[TBL] [Abstract][Full Text] [Related]
4. Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses.
Bestetti A; Capozza A; Lacerenza M; Manfredi L; Mancini F
Clin Nucl Med; 2017 Feb; 42(2):83-87. PubMed ID: 27941374
[TBL] [Abstract][Full Text] [Related]
5. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
Asai H; Udaka F; Hirano M; Minami T; Oda M; Kubori T; Nishinaka K; Kameyama M; Ueno S
Parkinsonism Relat Disord; 2005 Dec; 11(8):499-502. PubMed ID: 16263322
[TBL] [Abstract][Full Text] [Related]
6. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
7. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
8. Irregular gastrointestinal drug absorption in Parkinson's disease.
Nyholm D; Lennernäs H
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):193-203. PubMed ID: 18248312
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
Pfeiffer RF; Isaacson SH; Pahwa R
Parkinsonism Relat Disord; 2020 Jul; 76():63-71. PubMed ID: 32461054
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Simms SL; Huettner DP; Kortagere S
Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
[TBL] [Abstract][Full Text] [Related]
13. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.
Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O
J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
15. DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
Shin CM; Lee YJ; Kim JM; Lee JY; Kim KJ; Choi YJ; Kim N; Lee DH
Parkinsonism Relat Disord; 2018 Sep; 54():84-89. PubMed ID: 29705555
[TBL] [Abstract][Full Text] [Related]
16. Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.
Mahato K; Moon JM; Moonla C; Longardner K; Ghodsi H; Litvan I; Wang J
Angew Chem Int Ed Engl; 2024 Jul; 63(27):e202403583. PubMed ID: 38682251
[TBL] [Abstract][Full Text] [Related]
17. Delayed gastric emptying in Parkinson's disease.
Marrinan S; Emmanuel AV; Burn DJ
Mov Disord; 2014 Jan; 29(1):23-32. PubMed ID: 24151126
[TBL] [Abstract][Full Text] [Related]
18. The long-duration action of levodopa may be due to a postsynaptic effect.
Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
[TBL] [Abstract][Full Text] [Related]
19. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Pierantozzi M; Pietroiusti A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Frasca S; Galante A; Marciani MG; Stanzione P
Neurol Sci; 2001 Feb; 22(1):89-91. PubMed ID: 11487216
[TBL] [Abstract][Full Text] [Related]
20. [Management of autonomic dysfunction in Parkinson's disease].
Crespo-Burillo JA; Alarcia-Alejos R
Rev Neurol; 2015 Apr; 60(8):355-64. PubMed ID: 25857860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
